Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ25DI
|
|||
| Drug Name |
227Th-labelled MSLN-TTC
|
|||
| Synonyms |
BAY2287411
Click to Show/Hide
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Epithelioid mesothelioma [ICD-11: 2F10 ] | Phase 1 | [1] | |
| Company |
Bayer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | . | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03507452) First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin. U.S. National Institutes of Health. | |||
| REF 2 | Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.